Navigation Links
Rapamycin rescues learning, memory in Alzheimer's mouse model

SAN ANTONIO (Feb. 24, 2010) Rapamycin, a drug that keeps the immune system from attacking transplanted organs, may have another exciting use: fighting Alzheimer's disease.

Rapamycin rescued learning and memory deficits in a mouse model of Alzheimer's, a team from The University of Texas Health Science Center at San Antonio reported Tuesday (Feb. 23).

The study, in the Journal of Biological Chemistry, offers the first evidence that the drug is able to reverse Alzheimer's-like deficits in an animal model, said the senior author, Salvatore Oddo, Ph.D., assistant professor in the Department of Physiology of the UT Health Science Center San Antonio.

Tissue evidence

Rapamycin also reduced lesions in the brains of the mice, the team found. The lesions are similar to those seen in the brains of people who died with Alzheimer's.

"Our findings may have a profound clinical implication," said Dr. Oddo, who is a member of the university's Barshop Institute for Longevity and Aging Studies. "Because rapamycin is a U.S. Food and Drug Administration-approved drug, a clinical trial using it as an anti-Alzheimer's disease therapy could be started fairly quickly."

Last year three institutions, including the Barshop Institute, announced that rapamycin extended the life span of aged research mice at each of the sites. It was the first pharmacologic intervention shown to extend life in an animal model of aging.

Study method

For 10 weeks the mice that model Alzheimer's disease were fed chow containing rapamycin. At the start of treatment the mice were 6 months old, roughly the age of young adults, but already exhibited indications of learning and memory deficits and brain lesions.

At the end of the 10 weeks, the mice were tested in a contraption called the Morris water maze, sort of a miniature swimming pool used to assess learning and memory in rodents. At the end of the behavioral tests, the brains of the mice were analyzed to determine the effects of rapamycin on the lesions that indicate Alzheimer's.

Promise remains to be determined

Rapamycin, a bacterial product first isolated in soil from the island Rapa Nui in the South Pacific, also is being tested in cancer research studies. Rapa Nui is commonly known as Easter Island and is distinguished by ancient monoliths with faces.

"While it remains to be determined whether our results obtained in mice could be translated in people, we are very excited as these findings may lead to a new therapeutic intervention to treat Alzheimer's," Dr. Oddo said.


Contact: Will Sansom
University of Texas Health Science Center at San Antonio

Related medicine news :

1. New form of stem cell communication rescues diseased neurons
2. Drug rescues memory lost to Alzheimers disease
3. Foundation Rescues 500 Shelters and Rescue Groups Nationwide with $1 Million Worth of Generators
4. Chicago Mayor Honors Astellas Excellence in Learning, Development
5. KMSI Announces KMx Update That Provides eLearning, Knowledge Management and Collaboration Tools for Apple iPhone and Other Mobile Devices
6. Engineer: Computer learning, electrical stimulation offer hope for paralyzed
7. Brain Switchboard Separates Learning, Remembering
8. Brain scientist shedding light on learning, memory
9. Bioethics memory aid can help assess patient decision-making capacity in medical emergencies
10. Memory Loss Supplement Manufacturer Partners With Nationally-Syndicated Radio Host John Tesh
11. To Boost Your Memory, Take a Break
Post Your Comments:
Related Image:
Rapamycin rescues learning, memory in Alzheimer's mouse model
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... Indosoft Inc., ... inclusion of an application server to improve system efficiency and reliability. , The new ... many of these standards, the system avoids locking itself into a specific piece of ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical ... once again for its stellar workplace culture with the company’s Cincinnati office being ... Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is ... One Beat ” campaign. The partnership between the two groups began in 2014 with ... International’s cause. , MAP International was founded in 1954 and is an international Christian-based ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... and athletic programs, launches new Wimbledon Athletics Facebook page to educate ... athletes for unsuspected cardiac abnormalities. About 2,000 people under the age of 25 ...
(Date:11/25/2015)... Calif. (PRWEB) , ... November 25, 2015 , ... Beddit® ... and Beddit Classic sleep tracking systems. The new app features a more intuitive SleepScore™ ... and understand how well you slept. The SleepScore is created by a proprietary algorithm. ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Therapeutic Drug Monitoring (TDM) ... Competitive Intelligence, Emerging Opportunities"  report to ... ) has announced the addition of ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
Breaking Medicine Technology: